Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 47 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives
Patents for A61K 47 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives (171,128)
03/2010
03/17/2010CN101669910A Preparation of cefobutazine sodium proliposome
03/17/2010CN101669909A Biological adhesive liposome preparation for eyes and preparation method thereof
03/17/2010CN101669907A Oridonin emulsion
03/17/2010CN101669906A Praziquantel injection, preparation method and application thereof
03/17/2010CN101669905A Thymosin alpha1 injection-type subcutaneous implant
03/17/2010CN101669904A Epoprostanol lipid nanoparticle and preparation method thereof
03/17/2010CN101669903A Preparation method of ibuprofen aminophenol injection
03/17/2010CN101669902A Polyene phosphatidyl choline injection and preparation method thereof
03/17/2010CN101669901A Liquid preparation for dosing eyes and method for making the same
03/17/2010CN101669900A Polymeric delivery formulations of leuprolide with improved efficacy
03/17/2010CN101669899A Sustained-release implant taking maize protein as main framework material or matrix and use thereof
03/17/2010CN100594027C Percutaneous medicine of strychnine, toxiferine, securinine and salt thereof
03/16/2010US7678882 Polyamino acids functionalized by at least one hydrophobic group and the therapeutic application thereof
03/16/2010US7678836 Method for rendering a contact lens wettable
03/16/2010US7678827 Non-polymeric lipophilic pharmaceutical implant compositions for intraocular use
03/16/2010US7678824 Methods for treatment with bucindolol based on genetic targeting
03/16/2010US7678782 Bile-acid derived compounds for enhancing oral absorption and systemic bioavailability of drugs
03/16/2010US7678776 Inclusion complexes of butylphthalide with cyclodextrin or its derivatives, a process for their preparation and the use thereof
03/16/2010US7678771 comprising L-lysine-d-amphetamine or salts; for treating attention deficit hyperactivity disorder
03/16/2010US7678770 Abuse-resistant amphetamine prodrugs
03/16/2010US7678759 Diagnosis and treatment of neuroectodermal tumors
03/16/2010US7678378 Compounds for intracellular delivery of therapeutic moieties to nerve cells
03/16/2010US7678366 for high penetration into fingernails and toenails; contains humectant for trapping water and liquid nail lacquer containing film forming agent
03/16/2010US7678146 May be used for medical indications, such as an implantable or injectable endoprostheses for mammoplastic reconstruction, implantable or injectable endoprostheses for treating (reflux) oesophagitis, and for body contouring of various body parts
03/16/2010CA2554169C Myocardial perfusion imaging using adenosine receptor agonists
03/16/2010CA2510058C Improved pharmaceutical botulinum toxin compositions
03/16/2010CA2493277C Antipyrotic and method of manufacturing the same
03/16/2010CA2492467C Injectable depot formulation comprising crystals of iloperidone
03/16/2010CA2463517C Ph responsive biodegradable polylactic acid derivatives forming polymeric micelles and uses thereof for poorly water soluble drug delivery
03/16/2010CA2432006C Pharmaceutical preparation with retarding active ingredient release, method for its production and its use
03/16/2010CA2431521C Steroid hormone products and methods for preparing them
03/16/2010CA2415378C Oral pharmaceutical composition with controlled release and prolonged absorption
03/16/2010CA2395121C Composition, in particular cosmetic or dermatological composition, containing oligosaccharides and preparation method and cosmetic treatment method
03/16/2010CA2390047C Valnemulin formulation
03/16/2010CA2376986C Method for purification of proteins
03/16/2010CA2368617C Hydrogel-forming system with hydrophobic and hydrophilic components
03/16/2010CA2362772C Pharmaceutical formulation for intraveous or intramuscular octreotide administration
03/16/2010CA2296334C A dispensing device and method for forming material
03/16/2010CA2160693C Oral drug delivery compositions and methods
03/11/2010WO2010028389A1 Image-guided energy deposition for targeted drug delivery
03/11/2010WO2010028216A2 Porphyrazine optical and dual optical/mr contrast and therapeutic agents
03/11/2010WO2010028101A1 Method for making cetirizine tablets
03/11/2010WO2010027766A1 Lyophilized formulatons of engineered anti-il-23p19 antibodies
03/11/2010WO2010027513A2 Methods for killing psma-expressing, taxane-resistant cancer cells
03/11/2010WO2010027508A1 Methods for diagnosis or treatment of amyloidosis by targeting hyper-sulfated proteoglycans present in amyloid
03/11/2010WO2010027498A2 Compositions and methods for inducing satiety and treating non-insulin dependent diabetes emillitus, pre-diabetic symptoms, insulin resistance and related disease states and conditions
03/11/2010WO2010027479A2 Mucosal delivery of therapeutic molecules, proteins, or particles coupled to ceramide lipids
03/11/2010WO2010027340A1 Pharmaceutical compositions composing entakapon, levodopa and karbidoba
03/11/2010WO2010027101A1 Solid preparation for medical use
03/11/2010WO2010027014A1 Method for improving absorption of s-adenosyl-l-methionine, and composition having improved s-adenosyl-l-methionine absorption
03/11/2010WO2010026993A1 Method for improving absorbability of preparation, and preparation having improved absorbability
03/11/2010WO2010026946A1 Flavor improving agent
03/11/2010WO2010026781A1 Particles, method for producing same, and gel
03/11/2010WO2010026766A1 Agent for treating myelofibrosis
03/11/2010WO2010026760A1 Compositions wherein bioactive components are stably sealed
03/11/2010WO2010026701A1 Osteogenesis promoter comprising [4-(methylthio)phenylthio]methanebisphosphonic acid or pharmaceutically acceptable salt thereof as active ingredient
03/11/2010WO2010026537A1 Novel multimodular assembly useful for intracellular delivery
03/11/2010WO2010025632A1 A methods for preparing the clathrate compound of steroid medicines utilizing hydrotalcite as carrier
03/11/2010WO2010025630A1 Sodium cholate-included prednisone intercalated layered double hydroxides and preparation method thereof
03/11/2010WO2010009065A9 Organic compounds
03/11/2010WO2010005732A3 Composition and method of preparation of release systems for constant (zero-order) release of active agents
03/11/2010WO2010005723A3 Drug loaded polymeric nanoparticles and methods of making and using same
03/11/2010WO2010005721A3 Drug loaded polymeric nanoparticles and methods of making and using same
03/11/2010WO2010004513A3 Peptides and their use as carriers into cancer cells
03/11/2010WO2010001267A3 Delivery product for topical compositions
03/11/2010WO2009157711A3 Gastro-retentive porous tablet and method for preparing same
03/11/2010WO2009156691A3 Novel inverse latices that are free of oxyethylene derivatives, and cosmetic, dermocosmetic, dermopharmaceutical or pharmaceutical compositions comprising same
03/11/2010WO2009156690A3 Novel inverse latices based on fatty alcohol ethers, and cosmetic, dermocosmetic, dermopharmaceutical or pharmaceutical compositions comprising same
03/11/2010WO2009145594A3 Drug delivery carrier
03/11/2010WO2009134079A9 Pharmaceutical formulation
03/11/2010WO2009134056A9 Pharmaceutical formulation
03/11/2010WO2009129433A4 Alpha adrenergic receptor agonists for treatment of degenerative disc disease
03/11/2010WO2009100176A3 Pharmaceutical dosage form for oral administration of tyrosine kinase inhibitor
03/11/2010WO2009056322A8 Foam stabilizer for a sterilization composition
03/11/2010US20100063164 Transparent zinc sulphide having a high specific surface area
03/11/2010US20100063140 Water-soluble compositions of bioactive lipophilic compounds
03/11/2010US20100063034 Conjugated psychotropic drugs and uses thereof
03/11/2010US20100063010 Method for administering a spill resistant pharmaceutical system
03/11/2010US20100063008 Gelatinous elastomer compositions
03/11/2010US20100062988 Chewable sustained release formulations
03/11/2010US20100062973 Production of bioactive glycoproteins from inactive starting material
03/11/2010US20100062970 Synthesis of propyl phenoxy ethers and use as delivery agents
03/11/2010US20100062968 Novel strategies for delivery of active agents using micelles and particles
03/11/2010US20100062967 Coated lipid complexes and their use
03/11/2010US20100062067 Compositions comprising macromolecular assemblies of lipid and surfactant
03/11/2010US20100062049 Aqueous formulation for selective targeting and delivering gene to cancer cells
03/11/2010US20100062041 Skin sunstitutes, preparation methods and uses thereof
03/11/2010US20100062036 Multiblock Copolymers with Shape-Memory Properties
03/11/2010US20100062024 Biologically Active Hemagglutinin From Type A Clostridium Botulinum and Methods of Use
03/11/2010US20100062008 Drug conjugates and their use for treating cancer, an autoimmune disease or an infectious disease
03/11/2010US20100061983 Method of inhibiting leukocytes with human cxc chemokine receptor 3 antibody
03/11/2010CA2735709A1 Agent for treating myelofibrosis
03/11/2010CA2734919A1 Lyophilized formulatons of engineered anti-il-23p19 antibodies
03/11/2010CA2734908A1 Compositions of pd-1 antagonists and methods of use
03/11/2010CA2734691A1 Method for making cetirizine tablets
03/11/2010CA2734525A1 Sustained release formulations using non-aqueous carriers
03/10/2010EP2161291A2 Polymer
03/10/2010EP2161037A2 Camptothecin-Somatostatin conjugates
03/10/2010EP2161036A1 Cellulose fine core particle, and method for production thereof
03/10/2010EP2161021A1 Medicinal film preparation with rapidly dissolving property and flexibility
1 ... 513 514 515 516 517 518 519 520 521 522 523 524 525 526 527 528 529 530 531 532 533 ... 1712